CNRS

SIAM Announces Class of 2024 Fellows

Retrieved on: 
Jeudi, mars 28, 2024
CNRS, Editorial, Mathematics, Sorbonne University, Climate change, Algorithm, Masaryk University, Utrecht University, Data science, State university system, Cornell University, Systems theory, University of Utah, City University, University of Massachusetts, Research, University of British Columbia, Platelet, University, Software, IBM, University of Cambridge, University of Exeter, Statistics, Industrial, Rutgers University, University of Zurich, University of Waterloo, Stanford University, Virginia Tech, Probability, Lehigh University, Engineering, Lawrence Berkeley National Laboratory, Information technology

Philadelphia, PA, March 28, 2024 (GLOBE NEWSWIRE) -- Society for Industrial and Applied Mathematics (SIAM) is pleased to announce the 2024 Class of SIAM Fellows.

Key Points: 
  • Philadelphia, PA, March 28, 2024 (GLOBE NEWSWIRE) -- Society for Industrial and Applied Mathematics (SIAM) is pleased to announce the 2024 Class of SIAM Fellows.
  • Through their various contributions, SIAM Fellows form a crucial group of individuals helping to advance the fields of applied mathematics, computational science, and data science.
  • Hans De Sterck, University of Waterloo, is being recognized for contributions to scientific computing methods including multilevel and nonlinear solvers, and for exemplary scientific leadership and service to SIAM.
  • Fred S. Roberts, Rutgers University, is being recognized for distinguished research in discrete mathematics, leadership of major research centers, and service to SIAM.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Retrieved on: 
Lundi, avril 8, 2024
Research, Technology, Semiconductor, Genetics, Health Technology, Nanotechnology, Biotechnology, Hardware, Health, Science, CNRS, CPMAS, 2000s, HCN, Membrane, Corporation, DNP, NMR, Bruker, Hertz, Protein, Multimedia, MAS, BRKR, WB, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
  • Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries.
  • The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates.
  • In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Mercredi, mars 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5

Retrieved on: 
Mardi, mars 26, 2024
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, CNRS, Neurology, AAV, Motivation, Environment, Scientific method, Patient, CTA, DSM-IV codes, Biomarker, Research, ANSM, University, EMA, European Medicines Agency, Clinical trial, Therapy, Muscular dystrophy, Safety, Pathology, Weakness, Cardiomyopathy, Pharmaceutical industry

This authorization was first granted by the Italian Medicines Agency (AIFA), then by the French Medicines Agency (ANSM).

Key Points: 
  • This authorization was first granted by the Italian Medicines Agency (AIFA), then by the French Medicines Agency (ANSM).
  • Giacomo Comi, Full Professor of Neurology at the University of Milan (Italy), and principal investigator of this trial.
  • ATA-200, a gene therapy candidate for LGMD2C/R5, delivers a normal copy of the gene for production of γ-sarcoglycan protein.
  • In addition to its LGMD2C/R5 gene therapy, Atamyo is developing a clinical trial with ATA-100 gene therapy for LGMD2I/R9, related to deficiencies in FKRP; and is in IND-enabling studies for LGMD2A/R1, related to deficiencies in calpain protein.

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
Jeudi, mars 7, 2024
Therapy, CNRS, Target, Newcastle University, Facial muscles, Biotechnology, Professor, Teaching hospital, SAB, Neuromuscular disease, Ageing, Leiden University Medical Center, HD, DMD, Duchenne muscular dystrophy, Inflammation, LUMC, Mitochondrion, Gene therapy, Scientific method, Genetics, Knowledge, Leibniz Association, Publication, Translational research, Respiratory disease, Research, COPD, Pharmaceutical industry

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Retrieved on: 
Mardi, mars 5, 2024
CNRS, Regeneration, Crohn's disease, EIC, Exosome, Quality of life, Fistula, Stenosis, B cell, Patient, Fibrosis, Intellectual property, Congress, Research, ECCO, Pharmaceutical industry

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Key Points: 
  • Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
  • This new worldwide license marks a significant step forward in EVerZom's mission to bring innovative exosome-based therapeutic solutions to patients suffering from serious digestive diseases.
  • Paris, March 5, 2024 - EVerZom, a CNRS/Université Paris Cité spin-off specializing in exosomes, has announced the signature of a second exclusive license agreement with Erganeo for the development of EVerGel ™, a drug candidate tailored for the healing of digestive tissues.
  • EVerZom's first clinical application focuses on digestive tissue regeneration using naive exosomes derived from stem cells encapsulated in a gel called EVerGel ™.

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies

Retrieved on: 
Mardi, janvier 30, 2024
Transfer, Partnership, Curie Institute (Paris), Cell, AI, Immunotherapy, DNA, Research, Rupture, Patient, TREX1, Artificial intelligence, Drug design, Ligand, CNRS, Protein, HPC, Biology, Metastasis, University, Cancer

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.

Key Points: 
  • High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.
  • These will then be biologically validated and biochemically characterized by Institut Curie and the University of Bordeaux respectively.
  • This collaborative approach reflects the shared commitment of Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux to explore innovative approaches to the development of more targeted and effective cancer therapies.
  • We are delighted and honored to be working with the Institut Curie & the University of Bordeaux along these lines."

Global Times: French scholars reflect on 60 years of China-France friendship

Retrieved on: 
Mercredi, janvier 31, 2024
Book, Growth, Analects, Research, Language, History, Translation, Confucianism, Science, Classic, Museum, Confucius, Friends, Collection, School, Confucius Institute, Xi, Beauty, CNRS, Literature, City, Languages of Asia, Education, Daniel, Culture, Collaboration, Student, Global Times, Qin dynasty, Pleasure, Real-time, Tourism

The early translations of The Analects of Confucius inspired French thinkers Montesquieu and Voltaire, said Macron.

Key Points: 
  • The early translations of The Analects of Confucius inspired French thinkers Montesquieu and Voltaire, said Macron.
  • Born in 1948, Mathieu studied at the National Institute for Oriental Languages and Civilizations, majoring in Russian and Chinese language and culture.
  • Through reading, French and Chinese readers can discover each other and get to know each other better," he told the Global Times.
  • Increased university exchanges, a surge in cultural tourism and a proliferation of translations have forged numerous direct and indirect links.

Stellantis Ventures Invests in Tiamat and Affordable Sodium-Ion Battery Technology

Retrieved on: 
Vendredi, janvier 12, 2024
CNRS, BEV, Chemistry, Cobalt, Sodium, Scientific method, Carbon, Lithium, EV, Dare, Electric battery

Investment in Tiamat supports Stellantis mission for clean, safe and affordable mobility with a wide portfolio of battery chemistries

Key Points: 
  • Investment in Tiamat supports Stellantis mission for clean, safe and affordable mobility with a wide portfolio of battery chemistries
    Sodium-ion battery chemistry holds promise of lower costs, increased sustainability, better low-temperature performances and faster charging capability
    AMSTERDAM, January 12, 2024 – Stellantis Ventures, the corporate venture fund of Stellantis N.V., today announced its participation as a strategic investor in Tiamat, a France-based company that is developing and commercializing sodium-ion battery technology.
  • Tiamat was one of 11 top-performing technology start-ups honored with a Stellantis Ventures Award in 2023 , and is the first company in the world to have recently commercialized a sodium-ion technology in an electrified product.
  • The investment supports Stellantis’ mission to provide clean, safe and affordable mobility to customers around the world.
  • Sodium-ion technology holds the promise of a more cost-effective energy storage compared with today’s widely used lithium-ion battery technology.

Depixus Launches Technology Access Program With First MAGNA One™ Instrument Placement

Retrieved on: 
Jeudi, janvier 4, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, RNA, Dicarboxylic acid, Multimedia, Physics, DNA, Professor, CNRS, Enzyme, Interactome, ENS

Interactomics pioneer Depixus has launched its game-changing MAGNA™ technology access program with the deployment of the first MAGNA One™ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at the École Normale Supérieure (ENS), Paris.

Key Points: 
  • Interactomics pioneer Depixus has launched its game-changing MAGNA™ technology access program with the deployment of the first MAGNA One™ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at the École Normale Supérieure (ENS), Paris.
  • View the full release here: https://www.businesswire.com/news/home/20240104503352/en/
    Depixus MAGNA One instrument being used by Professor Jean-François Allemand, ENS, Paris.
  • (Photo: Business Wire)
    Based on magnetic force spectroscopy, MAGNA is the first technology to deliver direct, simultaneous, real-time measurements of the dynamics of many thousands of individual molecular interactions.
  • Feedback from this placement will enable Depixus to further improve the technology prior to full commercial launch later in 2024.